You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Risk of patent expiration on Humira and Gilead Sciences positive hepatitis C trial results weighed on shares last month.
Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences (GILD 0.25%), shares in AbbVie, Inc (ABBV -0.93%) tumbled by 12.8% last month.
AbbVie is under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. In the following slideshow, I highlight the risks to AbbVie and how it hopes to overcome them.
Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
